Man is the only animal that blushes - or needs to." - Mark Twain
Today, we take a look at a small 'Tier 4' developmental firm named Eiger BioPharmaceuticals (EIGR). There also has been some small insider buying in this concern in January meriting a 'deep dive'. A full investment analysis follows in the paragraphs below.
Company Overview
Eiger BioPharmaceuticals is a Palo Alto, California-based, late-stage biopharmaceutical company that IPO'd in 2014. The company is focused on building a portfolio of well-characterized drugs for rare diseases. Furthermore, they seek to reduce